Ad Code: 27441
DMTs Lower Multiple Sclerosis Relapse Risk During Reproductive Therapy
May 23, 2022
In women with multiple sclerosis (MS) and clinically isolated syndrome (CIS), continuing disease...
Read MoreSpinal Cord Atrophy Indicates “Silent Progression”
May 23, 2022
In patients in the earlier stages of MS, an accelerated rate of spinal cord atrophy can indicate...
Read MoreWhite Matter Iron Rim Lesions Predict Worse Disability in Multiple Sclerosis
May 20, 2022
“Identifying an accurate prognostic biomarker in individuals with multiple sclerosis (MS) is...
Read MoreOzanimod Safe & Effective in DAYBREAK Open-Label Extension
Mar 28, 2022
For patients with multiple sclerosis (MS), ozanimod provides continued control of disease activity...
Read MoreFibulin-2, An Extracellular Matrix Remyelination Inhibitor
Mar 21, 2022
For a study, the researchers sought to assess FBLN2 expression in MS and EAE lesions to see if the ECM molecule could alter oligodendrocyte maturation and remyelination. The study team discovered elevated levels of FBLN2 in EAE...
Read MoreSex, Hormones, and Age Interactions in MS Prognosis
Mar 21, 2022
The researchers sought to examine aging-related mechanisms in MS prognosis for a study. They also sought to determine sex-specific elements that influence MS prognosis and explore the link between sex, hormones, and aging in MS...
Read MoreUse of Electronic Health Records as Prognostic Indicator
Mar 21, 2022
For a study, the researchers sought to undertake 2 analyses. They combined EHR data with gold-standard data from a well-established clinic-based research registry. First, they used a 2-stage process to develop models that...
Read MoreCognitive Function Improvement in the Patients With MS
Mar 21, 2022
For a study, the researchers sought to compare the cognitive effects of active vs sham tDCS combined with adaptive cognitive training (aCT) administered as an at-home intervention in adults with MS in a randomized...
Read MoreSerum Neurofilament For Gray Matter Atrophy And Clinical Impairment in MS
Mar 21, 2022
For a study, the researchers examined the relationship between sNfL levels throughout a 2-year period and clinical disability and gray matter (GM) atrophy after 10 years in early relapsing-remitting MS (RRMS) patients. A total...
Read MoreBenefits of Disease-Modifying Therapy in MS Patients
Mar 21, 2022
For a study, the researchers sought to forecast the conditional average treatment effect (CATE) for people on anti-CD20 monoclonal antibodies and laquinimod for a study. For this, researchers used a multitask multilayer...
Read MoreSARS-CoV-2 Vaccine Efficacy in Multiple Sclerosis
Mar 21, 2022
SARS-CoV-2 induced Coronavirus Disease 19 (COVD-19), a highly transmissible and potentially lethal illness, became a global pandemic in early 2020. Several vaccinations against this virus have been developed, including 2 novel...
Read MoreLevels of Serum Neurofilament Light and Glial Fibrillary Acidic Protein at MS Onset
Mar 21, 2022
For a study, the researchers sought to see if early serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) levels, assessed at baseline and 1 year later, provide predictive value to models of commonly...
Read MoreUse of Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis
Mar 21, 2022
Patients with severe multiple sclerosis (MS) were increasingly receiving autologous hematopoietic stem cell transplantation (aHSCT). For a study, the researchers sought to look at the short and long-term results after aHSCT in...
Read MoreCognitive Processing Speed in Multiple Sclerosis Patients
Mar 21, 2022
In patients with multiple sclerosis (MS), cognitive dysfunction particularly slowed cognitive processing speed (CPS), was a key source of disability. Compared to intramuscular interferon (IFN) Beta-1a, the sphingosine...
Read MoreACTRIMS 2022 Kenneth P. Johnson Memorial Lecture
Mar 17, 2022
This year’s Kenneth P. Johnson Memorial Lecturer is Ruth Ann Marrie, MD, PhD, FRCPC. ACTRIMS presents an annual lecture named in honor of the late Dr. Kenneth P. Johnson who founded the foundation. The lecture provides an...
Read MoreWhat You Need to Know About ACTRIMS 2022
Mar 17, 2022
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) hosted the seventh annual forum, February 24-26. This year’s forum was themed Biomarkers in MS. Highlights of the forum include the Kenneth...
Read More